Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation

Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis

(2023) German Valenzuela-Rodriguez et al.   Journal of Clinical Medicine

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir

(2023) Supphachoke Khemla et al.   Drug Target Insights

Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies

(2023) Yuting Luo et al.   BIOMEDICINE & PHARMACOTHERAPY

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

(2022) Yongin Cho et al.   BMC Medicine

Pulmonary delivery of resveratrol-β-cyclodextrin inclusion complexes for the prevention of zinc chloride smoke-induced acute lung injury

(2022) Wanmei Wang et al.   DRUG DELIVERY

Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis

(2022) Chuangen Li et al.   GUT

A community based cross sectional study on the prevalence of dyslipidemias and 10 years cardiovascular risk scores in adults in Asmara, Eritrea

(2022) Oliver Okoth Achila et al.   Scientific Reports

Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway

(2022) Bin Jiang et al.   Molecular Metabolism

LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry

(2021) Elisenda Climent et al.   CARDIOVASCULAR DRUGS AND THERAPY

Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota

(2021) Fan Du et al.   Frontiers in Microbiology

Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

(2021) Xiang Li et al.   BIOMACROMOLECULES

Dietary phytochemicals as modulators of human pregnane X receptor

(2021) Jie Zhang et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Resveratrol and its derivative pterostilbene attenuate oxidative stress-induced intestinal injury by improving mitochondrial redox homeostasis and function via SIRT1 signaling

(2021) Yanan Chen et al.   FREE RADICAL BIOLOGY AND MEDICINE

Polyphenols and neuroprotection: Therapeutic implications for cognitive decline

(2021) Giuseppe Caruso et al.   PHARMACOLOGY & THERAPEUTICS

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

(2021) Dafeng Liu et al.   Diabetology & Metabolic Syndrome

Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy

(2020) Lili Dai et al.   BMC INFECTIOUS DISEASES

Metastasis-associated protein 1-mediated antitumor and anticancer activity of dietary stilbenes for prostate cancer chemoprevention and therapy

(2020) Anait S. Levenson   SEMINARS IN CANCER BIOLOGY

Real-life management of drug–drug interactions between antiretrovirals and statins

(2020) Perrine Courlet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resveratrol Alleviates Endoplasmic Reticulum Stress–Associated Hepatic Steatosis and Injury in Mice Challenged with Tunicamycin

(2020) Yanan Chen et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis

(2019) Taesik Gwag et al.   JOURNAL OF HEPATOLOGY

Sesamin, a Naturally Occurring Lignan, Inhibits Ligand-Induced Lipogenesis through Interaction with Liver X Receptor Alpha (LXRα) and Pregnane X Receptor (PXR)

(2019) Tsai-Sung Tai et al.   Evidence-based Complementary and Alternative Medicine

Resveratrol improves alcoholic fatty liver disease by downregulating HIF-1α expression and mitochondrial ROS production

(2017) Zhenhua Ma et al.   PLoS One

Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy

(2015) Kristine M. Erlandson et al.   CLINICAL INFECTIOUS DISEASES

Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms

(2014) Andreas Bitter et al.   ARCHIVES OF TOXICOLOGY

Resveratrol as an Inhibitor of Pregnane X Receptor (PXR): Another Lesson in PXR Antagonism

(2014) Tomas Smutny et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Resveratrol Suppresses the Inducible Expression of CYP3A4 Through the Pregnane X Receptor

(2014) Rongrong Deng et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Liver cirrhosis

(2014) Emmanuel A Tsochatzis et al.   LANCET

Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation

(2014) Soo Jin Yang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

(2014) Barbara Sjouke et al.   Lancet Diabetes & Endocrinology

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

(2013) Lake Li et al.   FOOD AND CHEMICAL TOXICOLOGY

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

(2013) João Marcus Oliveira Andrade et al.   NUTRITION

Role of CAR and PXR in xenobiotic sensing and metabolism

(2012) Yue-Ming Wang et al.   Expert Opinion on Drug Metabolism & Toxicology